Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 27 Jul 2026	HK$339.9b	HK$48.6b	HK$1.2b	34.6x	284.2x	7x
Wed, 24 Jun 2026	HK$284.1b	HK$48.5b	HK$1.2b	29.3x	240.4x	5.9x
Fri, 22 May 2026	HK$310.0b	HK$48.4b	HK$1.2b	29.2x	267.3x	6.4x
Sun, 19 Apr 2026	HK$349.0b	HK$48.2b	HK$1.1b	33.1x	305.7x	7.2x
Tue, 17 Mar 2026	HK$325.4b	HK$43.6b	HK$6.1b	37.6x	53.3x	7.5x
Thu, 12 Feb 2026	HK$390.3b	HK$43.5b	HK$6.1b	45.4x	64.2x	9x
Sat, 10 Jan 2026	HK$344.7b	HK$42.6b	HK$6.3b	46.4x	54.3x	8.1x
Mon, 08 Dec 2025	HK$310.0b	HK$42.1b	HK$6.3b	45.4x	49.5x	7.4x
Wed, 05 Nov 2025	HK$329.5b	HK$41.8b	HK$6.2b	47.8x	53.1x	7.9x
Fri, 03 Oct 2025	HK$396.3b	HK$41.9b	HK$6.2b	52.6x	63.8x	9.5x
Sun, 31 Aug 2025	HK$303.7b	HK$41.9b	HK$6.0b	57.2x	50.6x	7.3x
Tue, 29 Jul 2025	HK$285.7b	HK$37.2b	HK$2.7b	60.5x	104.2x	7.7x
Thu, 26 Jun 2025	HK$218.5b	HK$36.3b	HK$2.6b	28.5x	83.6x	6x
Sat, 24 May 2025	HK$194.9b	HK$36.2b	HK$2.6b	26.5x	74.9x	5.4x
Mon, 21 Apr 2025	HK$169.6b	HK$35.4b	HK$2.5b	24x	67.1x	4.8x
Wed, 19 Mar 2025	HK$228.4b	HK$32.7b	-HK$202,460,494.17	49.1x	-1128x	7x
Fri, 14 Feb 2025	HK$171.6b	HK$35.8b	-HK$1,060,919,669.78	52.7x	-161.7x	4.8x
Sun, 12 Jan 2025	HK$151.3b	HK$35.6b	-HK$1,062,130,458.29	62.6x	-142.5x	4.2x
Tue, 10 Dec 2024	HK$165.1b	HK$35.8b	-HK$1,057,872,578.99	59.3x	-156.1x	4.6x
Thu, 07 Nov 2024	HK$156.8b	HK$35.5b	-HK$665,828,377.13	40.1x	-235.5x	4.4x
Sat, 05 Oct 2024	HK$195.3b	HK$35.9b	-HK$652,704,448.85	44.4x	-299.2x	5.4x
Mon, 02 Sep 2024	HK$127.6b	HK$35.9b	-HK$659,504,477.72	25.6x	-193.4x	3.6x
Wed, 31 Jul 2024	HK$90.2b	HK$33.5b	HK$3.1b	17x	29.2x	2.7x
Fri, 28 Jun 2024	HK$90.2b	HK$33.4b	HK$3.1b	19.6x	29.4x	2.7x
Sun, 26 May 2024	HK$96.4b	HK$33.5b	HK$3.1b	29.5x	31.2x	2.9x
Tue, 23 Apr 2024	HK$99.4b	HK$33.6b	HK$3.1b	31.3x	32.1x	3x
Thu, 21 Mar 2024	HK$116.5b	HK$33.3b	HK$3.7b	49.9x	31.7x	3.5x
Sat, 17 Feb 2024	HK$125.1b	HK$32.5b	HK$3.0b	46.9x	41.4x	3.8x
Mon, 15 Jan 2024	HK$206.0b	HK$32.4b	HK$3.0b	85.9x	68.8x	6.4x
Wed, 13 Dec 2023	HK$205.8b	HK$32.3b	HK$3.0b	82.5x	69x	6.4x
Fri, 10 Nov 2023	HK$272.7b	HK$30.1b	HK$2.7b	48.2x	101.9x	9.1x
Sun, 08 Oct 2023	HK$236.4b	HK$30.2b	HK$2.7b	41.7x	88.3x	7.8x
Tue, 05 Sep 2023	HK$239.0b	HK$30.3b	HK$2.7b	42.7x	88.7x	7.9x
Thu, 03 Aug 2023	HK$236.3b	HK$28.4b	HK$2.7b	22.7x	86.5x	8.3x

Current Industry PE

Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 284x which is higher than its 3-year average PE of 30.7x.

The 3-year average PS ratio of 5.9x is lower than the industry's current PS ratio of 7.0x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have declined 24% per year over the last three years.
Meanwhile revenues for these companies have grown 20% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?


HK Market	2.48%
Healthcare	2.90%
Life Sciences	6.41%
Clinical Research and Equipment	6.41%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
1548 Genscript Biotech	HK$16.86	20.0% +HK$6.1b	-6.5%	PS4.9x
2269 WuXi Biologics (Cayman)	HK$38.76	1.3% +HK$2.1b	21.1%	PE28x
3696 InSilico Medicine Cayman TopCo	HK$47.98	7.6% +HK$1.9b	n/a	PS62.3x
1521 Frontage Holdings	HK$1.15	4.5% +HK$101.4m	-32.4%	PE43.8x
3880 Medtide	HK$23.74	1.9% +HK$62.4m	-29.6%	PE13.4x

Insilico Medicine Cayman Topco Ism6331 Phase I Clinical Data in Patients with Mesothelioma and Advanced Solid Tumors Accepted for Rapid Oral Presentation At Esmo Congress 2026

InSilico Medicine Cayman TopCo announced that the first-in-human Phase I clinical trial data for ISM6331, the Company’s novel AI-driven pan-TEAD inhibitor, has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026. Title: First-in-human Multicenter Phase 1 Study of ISM6331, an AI-Designed Pan-TEAD Inhibitor, in Patients with Mesothelioma or Other Advanced Solid Tumors. Presentation Number: 1004RO. Presentation Type: Rapid Oral presentation. Congress: ESMO Congress 2026 (Madrid, Spain | October 23-27, 2026). Date & Time: Sunday, October 25, 2026, 08:30-10:00 a.m, CEST. Room: Cordoba Auditorium – Hall 4. The Phase I clinical trial, conducted concurrently in China and the United States, was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of ISM6331 as a single agent in patients with advanced or metastatic malignant mesothelioma or other solid tumors. ISM6331 is a potent pan-TEAD inhibitor, which not only effectively targets tumors with abnormalities in the hippo pathway but also shows synergistic anti-tumor effects and overcomes drug resistance in combination therapy. The novel, non-covalent structure of ISM6331 was guided by Chemistry42’s structure-based drug design strategy. In preclinical studies, ISM6331 demonstrated broad anti-tumor efficacy, potent activity at low doses, and a favorable safety profile with favorable ADMET characteristics. In August 2024, ISM6331 was granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) of the U.S. for the treatment of mesothelioma, and the first patient was dosed in the global multicenter Phase I clinical trial of ISM6331 in January 2025.

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Insilico Medicine Cayman Topco Ism6331 Phase I Clinical Data in Patients with Mesothelioma and Advanced Solid Tumors Accepted for Rapid Oral Presentation At Esmo Congress 2026

Xtalpi Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026

WuXi Biologics (Cayman) Inc. to Report First Half, 2026 Results on Aug 25, 2026

COO & Executive Director recently sold HK$581k worth of stock

New minor risk - Share price stability

China Health Group Inc., Annual General Meeting, Jul 17, 2026

New minor risk - Share price stability

Zhejiang Taimei Medical Technology Co., Ltd. Announces Board and Committee Appointments, Effective June 23, 2026

Investor sentiment improves as stock rises 17%

Viva Biotech Holdings' (HKG:1873) Profits May Not Reveal Underlying Issues

Full year 2025 earnings released: EPS: CN¥0.066 (vs CN¥0.031 in FY 2024)